The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Graeme J. Hankey

FRACP

Department of Neurology

Royal Perth Hospital

197 Wellington Street

[email]@cyllene.uwa.edu.au

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • FRACP, Department of Neurology, Royal Perth Hospital, 197 Wellington Street. 1997 - 2012
  • Consultant Neurologist and Head of Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington Street, Australia. 2007
  • Stroke Unit, Royal Perth Hospital, WA. 1998 - 2005
  • Royal Perth Hospital, and Department of Medicine, University of Western Australia, Perth, Australia. 2001 - 2003
  • Royal Perth Hospital, and Department of Medicine, Australia. 1999

References

  1. Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial. Hankey, G.J., Eikelboom, J.W., Yi, Q., Lees, K.R., Chen, C., Xavier, D., Navarro, J.C., Ranawaka, U.K., Uddin, W., Ricci, S., Gommans, J., Schmidt, R. Stroke (2012) [Pubmed]
  2. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Hankey, G.J., Eikelboom, J.W., Yi, Q., Lees, K.R., Chen, C., Xavier, D., Navarro, J.C., Ranawaka, U.K., Uddin, W., Ricci, S., Gommans, J., Schmidt, R. Lancet. Neurol (2012) [Pubmed]
  3. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Hankey, G.J., Patel, M.R., Stevens, S.R., Becker, R.C., Breithardt, G., Carolei, A., Diener, H.C., Donnan, G.A., Halperin, J.L., Mahaffey, K.W., Mas, J.L., Massaro, A., Norrving, B., Nessel, C.C., Paolini, J.F., Roine, R.O., Singer, D.E., Wong, L., Califf, R.M., Fox, K.A., Hacke, W. Lancet. Neurol (2012) [Pubmed]
  4. Nutrition and the risk of stroke. Hankey, G.J. Lancet. Neurol (2012) [Pubmed]
  5. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Hankey, G.J., Johnston, S.C., Easton, J.D., Hacke, W., Mas, J.L., Brennan, D., Mak, K.H., Bhatt, D.L., Fox, K.A., Topol, E.J. Int. J. Stroke (2011) [Pubmed]
  6. Dabigatran etexilate: a new oral thrombin inhibitor. Hankey, G.J., Eikelboom, J.W. Circulation (2011) [Pubmed]
  7. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Hankey, G.J. Curr. Opin. Neurol. (2010) [Pubmed]
  8. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Hankey, G.J., Hacke, W., Easton, J.D., Johnston, S.C., Mas, J.L., Brennan, D.M., Bhatt, D.L., Fox, K.A., Topol, E.J. Stroke (2010) [Pubmed]
  9. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Hankey, G.J., Eikelboom, J.W. Lancet. Neurol (2010) [Pubmed]
  10. Management of cholesterol to reduce the burden of stroke in Asia: consensus statement. Hankey, G.J., Wong, K.S., Chankrachang, S., Chen, C., Crimmins, D., Frayne, J., Kim, J.S., Li, Y., Liou, C.W., Merican, J.S., Misbach, J., Navarro, J., Shinohara, Y., Wang, Y., Yoon, B.W. Int. J. Stroke (2010) [Pubmed]
  11. At last, a RE-LYable alternative to warfarin for atrial fibrillation. Hankey, G.J. Int. J. Stroke (2009) [Pubmed]
  12. Easily missed? Subarachnoid haemorrhage. Hankey, G.J., Nelson, M.R. BMJ (2009) [Pubmed]
  13. When the patient fails to respond to treatment: TIAs that go on, and on. Hankey, G.J. Pract. Neurol (2008) [Pubmed]
  14. How I interpreted the randomised trials of carotid angioplasty/stenting versus endarterectomy. Hankey, G.J. Eur. J. Vasc. Endovasc. Surg (2008) [Pubmed]
  15. Rate, degree, and predictors of recovery from disability following ischemic stroke. Hankey, G.J., Spiesser, J., Hakimi, Z., Bego, G., Carita, P., Gabriel, S. Neurology (2007) [Pubmed]
  16. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Hankey, G.J. Curr. Med. Res. Opin (2007) [Pubmed]
  17. Antiplatelet therapy for stroke prevention. Hankey, G.J. Curr. Atheroscler. Rep (2007) [Pubmed]
  18. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Hankey, G.J., Spiesser, J., Hakimi, Z., Carita, P., Gabriel, S. Neurology (2007) [Pubmed]
  19. Clinical update: management of stroke. Hankey, G.J. Lancet (2007) [Pubmed]
  20. Potential new risk factors for ischemic stroke: what is their potential?. Hankey, G.J. Stroke (2006) [Pubmed]
  21. Is plasma homocysteine a modifiable risk factor for stroke?. Hankey, G.J. Nature Clinical Practice. Neurology (2006) [Pubmed]
  22. Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population. Hankey, G.J., Eikelboom, J.W., Loh, K., Tang, M., Pizzi, J., Thom, J., Yi, Q. Cerebrovasc. Dis. (2005) [Pubmed]
  23. Secondary prevention of recurrent stroke. Hankey, G.J. Stroke (2005) [Pubmed]
  24. Homocysteine and stroke. Hankey, G.J., Eikelboom, J.W. Lancet (2005) [Pubmed]
  25. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. Hankey, G.J., Eikelboom, J.W. Neurology (2005) [Pubmed]
  26. Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No. Hankey, G.J. J. Thromb. Haemost. (2005) [Pubmed]
  27. Redefining risks after TIA and minor ischaemic stroke. Hankey, G.J. Lancet (2005) [Pubmed]
  28. Preventable stroke and stroke prevention. Hankey, G.J. J. Thromb. Haemost. (2005) [Pubmed]
  29. Vascular disease of the heart, brain and limbs: new insights into a looming epidemic. Hankey, G.J. Lancet (2005) [Pubmed]
  30. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Hankey, G.J. Cerebrovasc. Dis. (2004) [Pubmed]
  31. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?. Hankey, G.J., Klijn, C.J., Eikelboom, J.W. Stroke (2004) [Pubmed]
  32. Folic acid-based multivitamin therapy to prevent stroke: the jury is still out. Hankey, G.J., Eikelboom, J.W. Stroke (2004) [Pubmed]
  33. Clinical usefulness of plasma homocysteine in vascular disease. Hankey, G.J., Eikelboom, J.W., Ho, W.K., van Bockxmeer, F.M. Med. J. Aust. (2004) [Pubmed]
  34. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?. Hankey, G.J. Stroke (2003) [Pubmed]
  35. Long-term outcome after ischaemic stroke/transient ischaemic attack. Hankey, G.J. Cerebrovasc. Dis. (2003) [Pubmed]
  36. Evacuation of intracerebral hematoma is likely to be beneficial--against. Hankey, G.J. Stroke (2003) [Pubmed]
  37. Antiplatelet drugs. Hankey, G.J., Eikelboom, J.W. Med. J. Aust. (2003) [Pubmed]
  38. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?. Hankey, G.J., Eikelboom, J.W. Stroke (2003) [Pubmed]
  39. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Hankey, G.J., Jamrozik, K., Broadhurst, R.J., Forbes, S., Anderson, C.S. Stroke (2002) [Pubmed]
  40. Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?. Hankey, G.J. Stroke (2002) [Pubmed]
  41. Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. Hankey, G.J. Curr. Opin. Lipidol. (2002) [Pubmed]
  42. Homocysteine and stroke. Hankey, G.J., Eikelboom, J.W. Curr. Opin. Neurol. (2001) [Pubmed]
  43. Current oral antiplatelet agents to prevent atherothrombosis. Hankey, G.J. Cerebrovasc. Dis. (2001) [Pubmed]
  44. Management of the first-time transient ischaemic attack. Hankey, G.J. Emerg. Med. (Fremantle) (2001) [Pubmed]
  45. Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. Hankey, G.J., Eikelboom, J.W. CNS. Drugs (2001) [Pubmed]
  46. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Hankey, G.J., Sudlow, C.L., Dunbabin, D.W. Cochrane. Database. Syst. Rev (2000) [Pubmed]
  47. Transient ischaemic attacks and stroke. Hankey, G.J. Med. J. Aust. (2000) [Pubmed]
  48. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Hankey, G.J., Jamrozik, K., Broadhurst, R.J., Forbes, S., Burvill, P.W., Anderson, C.S., Stewart-Wynne, E.G. Stroke (2000) [Pubmed]
  49. Homocysteine and vascular disease. Hankey, G.J., Eikelboom, J.W. Lancet (1999) [Pubmed]
  50. Smoking and risk of stroke. Hankey, G.J. J. Cardiovasc. Risk (1999) [Pubmed]
  51. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Hankey, G.J., Warlow, C.P. Lancet (1999) [Pubmed]
  52. Stroke prediction and prevention by carotid endarterectomy: keep an eye on the doughnut and not just the hole. Hankey, G.J. Cerebrovasc. Dis. (1999) [Pubmed]
  53. One year after CAPRIE, IST and ESPS 2. Any changes in concepts?. Hankey, G.J. Cerebrovasc. Dis. (1998) [Pubmed]
  54. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Hankey, G.J., Jamrozik, K., Broadhurst, R.J., Forbes, S., Burvill, P.W., Anderson, C.S., Stewart-Wynne, E.G. Stroke (1998) [Pubmed]
  55. Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop. Hankey, G.J. Med. J. Aust. (1998) [Pubmed]
  56. Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials. Hankey, G.J., Hon, C. Stroke (1997) [Pubmed]
 
WikiGenes - Universities